Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Greece

Greece Articles

Industry

BMI View: We continue to view the drug shortage crisis in Greece with concern, especially as vulnerable patient groups are at risk. This latest development emphasises the exceptional... 2013-03-19


Industry

BMI View: The ongoing turmoil in Greece has culminated in a complete breakdown of the public healthcare system. Drug shortages have been exacerbated by opportunistic parallel exporters,... 2013-02-28


Industry

BMI View: We continue to hold a concerned view on the outlook of the Greek pharmaceutical market. Drugmakers face ceilings on margins, mandated price cuts and the possibility of unpaid... 2012-11-06


Industry

BMI View: We continue to hold a poor outlook for the Greek pharmaceutical market. Drugmakers, especially domestic producers, face the most challenging business environment in the EU.... 2012-10-29


Industry

BMI View: In our Q113 assessment, we have revised downward our Pharmaceuticals and Healthcare Risk/Reward Ratings (RRRs) for Central and Eastern Europe (CEE), mainly due to the attractiveness... 2012-10-03


Industry

BMI View: Following an internal workshop on the prospect of a Greek exit from the eurozone, BMI's Country Risk team have decided to continue to stick with our 'muddle through' scenario... 2012-05-31


Industry

BMI View: The ability and willingness of countries to pay back debts due to pharmaceutical companies across Europe is as important as the array of drug policy reforms that are enforcing... 2012-04-13


Industry

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05


Industry

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2012-03-12


Industry

BMI View: While some European pharmaceutical and healthcare companies are exposed to the private sector involvement (PSI) deal that has seen the value of state bonds issued to private... 2012-03-09

1 to 10 of 55 results
<< | < | 1 | 2 | 3 | 4 | 5 | 6 | > | >>
Insight